Why BGPT?
logo

Science's Data Search Engine

Results grounded in experimental data—not abstracts.







Press Enter ↵ to solve



    Fuel Your Discoveries




     Quick Answer


    The string **“Best Evidence: Meta-analysis on [topic] (requires author papers)”** is not evaluable as written because **the topic is unspecified**. From the supplied dataset, one concrete candidate “meta-analysis” is the psychosis neuroimaging ML meta-analysis (single vs multimodal). Its central quantitative claim is: in internal validation, **modalities differentiate psychosis vs controls with moderate accuracy**, with **rs-FC slightly higher**, while **multimodal provides limited extra benefit** under substantial heterogeneity and signs of bias.


     Long Answer


    Battle-test request: “Best Evidence: Meta-analysis on [topic]”

    Your provided evidence label is not testable because it does not specify the topic.
    Below, I evaluate the closest concrete meta-analysis present in your supplied raw research data: the psychosis neuroimaging ML meta-analysis.

    1) What is actually “meta-analysis” here?

    • Study type: PRISMA-guided systematic review and meta-analysis of machine-learning classification performance using whole-brain neuroimaging.
    • Core comparison: single-modality (T1, DTI, rs-FC) vs multimodal models.
    • Key pooled metrics: sensitivity & specificity in internal and external validation.
    • Critical context: substantial heterogeneity (I2 ~91.8%) and funnel-plot asymmetry consistent with potential bias.

    2) Visual: pooled classification accuracy by modality (internal validation)

    3) Visual: internal validation advantage vs external validation (key modality)

    4) Evidence battle-score: what’s credible vs fragile?

    Claim to evaluate What the meta-analysis reports Key reasons to be skeptical Confidence (from reported evidence quality)
    “All modalities distinguish psychosis vs controls with moderate accuracy.” Pooled internal sensitivity/specificity for T1 (~0.73/0.77), DTI (~0.71/0.73), rs-FC (~0.76/0.81), multimodal (~0.81/0.79). High heterogeneity (I2 ~91.8%); ML performance in internal validation is vulnerable to overfitting/data leakage (common failure mode in ML-neuroimaging literature, especially with design/reporting variation). Moderate (pooled signals exist, but dispersion/bias are large).
    “rs-FC has a slight advantage; multimodal adds limited benefit.” rs-FC internal ~0.76/0.81; multimodal internal ~0.81/0.79. External results: rs-FC often competitive vs T1 in the pooled extract. Multimodal benefit can be diluted by inconsistent fusion strategies, different preprocessing choices, and variable modality inclusion across studies; pooled multimodal vs unimodal comparisons are sensitive to which study configurations dominate. Moderate-to-weak (directional tendency, but heterogeneity + bias limit effect-size certainty).
    “External validation confirms generality.” External pooled metrics are lower than internal; external specificity/sensitivity provided for T1 and rs-FC in the extract. External validation coverage may be incomplete across modalities; pooled external metrics are still vulnerable to dataset overlap, protocol differences, and limited “independent” diversity in scanners/demographics. Weak-to-moderate (generalization appears worse, and uncertainty remains high).

    5) What would most likely disprove these conclusions? (falsification targets)

    • Large, rigorously independent external datasets where multimodal fusion consistently beats best unimodal performance after controlling for confounders (scanner/protocol, motion, preprocessing) would directly falsify the “limited added benefit” conclusion.
    • Reproducible near-ceiling performance across cohorts for any modality would challenge the “moderate accuracy + heterogeneity” framing.
    • Elimination of bias signals (e.g., funnel asymmetry) after standardization and improved reporting would reduce skepticism about effect sizes.

    6) Best critique of your placeholder “Best Evidence” format

    Why the placeholder fails scientific usability:
    • Missing topic => missing question, population, endpoints, and study designs.
    • Missing citation => cannot evaluate effect size, heterogeneity, risk of bias, or transitivity assumptions.
    • “Requires author papers” is incomplete: author papers are not a criterion; the bibliographic target must be specified (title/DOI) and the evidence class must be tied to the claim.
    If you tell me the topic (e.g., “multimodal neuroimaging for psychosis classification”, “topical fluoride preventing root caries”, etc.), I can locate the best available meta-analyses and then provide a quantified, skepticism-focused evidence grade.
    Use this to automatically fetch/triangulate the exact meta-analysis once you specify the real topic (since the placeholder is not evaluable as-is).


    Feedback:    

    Updated: April 29, 2026

     Top Data Sources ExportMCP


     Analysis Wizard



    It will structure the supplied modality metrics into plots/tables, compute internal-to-external deltas, and generate skepticism-focused summaries from reported heterogeneity/bias indicators.



     Hypothesis Graveyard


    “Multimodal always improves psychosis classification.” Rejected as best-supported pooled direction suggests limited incremental benefit with substantial heterogeneity and bias concerns.


    “rs-FC is universally best across all psychosis subtypes and acquisition protocols.” Not supported: external performance is lower and evidence is modality-specific with heterogeneity plus incomplete external coverage by modality.

     Science Art


    Best Evidence: Meta-analysis on [topic] (requires author papers) Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending